ArticleScientific reports2025
BIGH3 is a mediator of TGFβ-Induced collagen formation in fibrosis and pancreatic cancer and a potential therapeutic target.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Human trilayer engineered blood vessel reveals influence of fibroblasts on disease progression in model of Hutchinson-Gilford progeria.Science advances · 2026Article
- TGFBI in tumors and the tumor immune microenvironment: functional roles, mechanisms, and therapeutic targeting.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
Fibroblast-driven deposition of extracellular matrix, particularly type III collagen, is linked to poor outcomes in patients with liver fibrosis, fibrotic solid tumors such as hepatocellular carcinoma and pancreatic cancer as well as in patients with other fibrotic diseases. The pro-peptide of type III collagen (PRO-C3) serves as a serum biomarker of active collagen formation. PRO-C3 is elevated and prognostic in patients with liver fibrosis and pancreatic cancer, suggesting that targeting mechanisms behind PRO-C3 elevation could benefit these individuals. In this study, we sought to identify genetic variants associated with circulating PRO-C3 levels as potential therapeutic targets for fibrotic diseases and cancer. A genome-wide association study (GWAS) of the PERF cohort (n = 4968) identified variants in the gene TGFBI (BIGH3/βigH3), a known risk factor for tumor fibrosis, as associated with elevated PRO-C3. Further analyses of serum samples from patients with pancreatic ductal adenocarcinoma and liver fibrosis confirmed significant correlations between PRO-C3 and BIGH3 levels. Functional studies in a fibroblast model demonstrated that BIGH3 induces PRO-C3 in a dose-dependent manner, which was blocked by an anti-BIGH3 antibody, indicating a causal role. BIGH3 expression was observed in macrophages and fibroblasts, especially under TGFβ stimulation, positioning BIGH3 as a downstream mediator of TGFβ-induced fibrosis. Finally, blocking BIGH3 in a TGFβ-induced fibrosis model led to reduced PRO-C3 levels, demonstrating that BIGH3 is local mediator of pathological TGFβ signaling. This highlights that BIGH3 may be implicated in TGFβ-induced fibrosis and underscore the potential for treatment of pathological fibrotic processes by inhibiting BIGH3 in patients with elevated PRO-C3 levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.